Previous 10 | Next 10 |
Eiger BioPharmaceuticals ([[EIGR]] -5.6%) expects EMA approval for its Hutchinson-Gilford progeria syndrome treatment Zokinvy, and plans to start its Phase 3 HDV LIMT-2 ((Lambda)) trial, both in the second half of this year.Lambda is a well-tolerated interferon in development for HD...
Eiger BioPharmaceuticals Updates on 2020 Progress and 2021 Plans - Phase 3 HDV D-LIVR (Lonafarnib) Planned to Complete Enrollment in 2021 - Phase 3 HDV LIMT-2 (Lambda) Planned to Initiate in 2H21 - Zokinvy™ EMA Approval Expected in 2H21 - Strong Cash Position ...
Heading into 2021, Baird keeps a neutral view on Biotechnology despite higher expectations after the sector with a 26% gain in the iShares Nasdaq Biotechnology ETF (IBB) outperformed in 2020 compared to the 16% in the SPDR S&P 500 Trust ETF (SPY). The outlook is underpinned by uncertainty...
Two new breakout stocks for Week 1 of 2021 with better than 10% short-term upside potential. The MDA breakout picks completed 2020 up +73.4% beating the S&P 500 for the 4th consecutive year with avg annual returns of +43.8%. The streak of weekly picks gaining over 10% in less ...
Eiger is solely focused on rare disease opportunities with its big target being hepatitis delta virus. Eiger's first therapy Zokinvy just got approved which nets the company an important Priority Review Voucher that the company then sold and netted $47.5 million in cash. Despite t...
Eiger BioPharmaceuticals (EIGR) jumps 8% premarket after entering into an agreement to sell its Priority Review Voucher ((PRV)) for a lump sum payment of $95M.Eiger will retain 50% of the proceeds, or $47.5M, under the terms of the Collaboration and Supply Agreement with The Progeri...
BIO-key International (BKYI) +44% after partnering with Prominic.NET.Ideanomics (IDEX) +33% after increasing stake in e-Tractor company.Kaixin Auto Holdings (KXIN) +32%.DPW Holdings (DPW) +29% after entering new franchise program.CPS Technologies Corporation (CPS...
Eiger BioPharmaceuticals Sells Priority Review Voucher for $95 Million - Eiger and The Progeria Research Foundation will share proceeds 50/50 - Non-dilutive capital further strengthens Eiger's balance sheet PR Newswire PALO ALTO, Calif., Nov. 23, 2020 PALO ...
Eiger BioPharmaceuticals (EIGR) +11.6% after-hours on news that the U.S. Food and Drug Administration granted approval of its Zokinvy (lonafarnib) capsules to reduce the risk of death due to Hutchinson-Gilford progeria syndrome and for the treatment of some processing-deficient progeroid...
Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy™ (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies - Zokinvy increases survival by 2.5 years in children and young adults with Progeria ...
News, Short Squeeze, Breakout and More Instantly...
Eiger BioPharmaceuticals Inc. Company Name:
EIGR Stock Symbol:
NASDAQ Market:
Eiger BioPharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Nikola Corporation (NKLA) rose 6.5% to $0.95 on volume of 182,734,103 shares WiSA Technologies Inc. (WISA) fell 3.3% to $0.0235 on volume of 160,634,740 shares PROSHARES TRUST (SQQQ) rose 4.7% to $11.12 on volume of 151,373,755 shares...
A look at the top 10 most actives in the United States Sunshine Biopharma Inc. (SBFM) rose 76.0% to $0.1065 on volume of 290,483,542 shares CXApp Inc. (CXAI) rose 151.0% to $6.15 on volume of 236,739,031 shares Nikola Corporation (NKLA) fell 1.0% to $1.03 on volume of 123,276,764 shares ...
Announces “Stalking Horse” Agreement for the Sale of Zokinvy ® (lonafarnib) Patient Access to Zokinvy ® to Continue Uninterrupted PALO ALTO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) today ...